A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1

Anthony D. Kelleher, Rebekah L. Puls, Mark Bebbington, David Boyle, Rosemary Ffrench, Stephen J. Kent, Sue Kippax, Damian F.J. Purcell, Scott Thomson, Handan Wand, David A. Cooper, Sean Emery

Research output: Contribution to journalArticleResearchpeer-review

59 Citations (Scopus)


An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 × 107 pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.

Original languageEnglish
Pages (from-to)294-297
Number of pages4
Issue number2
Publication statusPublished - 1 Jan 2006

Cite this